IRADIMED's Q3 Revenue Jumps 13.5%, Net Income Up 13.8%

Ticker: IRMD · Form: 10-Q · Filed: Nov 3, 2025 · CIK: 1325618

Sentiment: bullish

Topics: Medical Devices, MRI Compatible, Earnings Growth, Regulatory Risk, Supply Chain, Capital Expenditures, Healthcare Technology

TL;DR

**IRMD is crushing it with double-digit revenue and profit growth, but watch out for those regulatory hurdles and single-source suppliers.**

AI Summary

IRADIMED CORP (IRMD) reported robust financial performance for the nine months ended September 30, 2025, with revenue increasing by 13.5% to $61,122,101 from $53,852,954 in the prior year period. Net income also saw a significant rise of 13.8%, reaching $16,038,042 compared to $14,087,248 in the same period of 2024. Gross profit improved to $47,292,106 from $41,589,022, reflecting a healthy gross margin. The company's cash and cash equivalents grew to $56,526,151 as of September 30, 2025, up from $52,233,907 at December 31, 2024. Key business changes include a substantial increase in property and equipment, net, to $23,792,441 from $16,810,797, indicating significant capital expenditures. Risks highlighted include reliance on FDA and international regulatory clearances for medical devices and the sole-sourcing of certain key product components, which could materially impact operations if disrupted. The strategic outlook appears focused on continued growth, supported by increased investment in assets and strong operational cash flow, despite a decrease in net cash provided by operating activities to $19,024,428 from $19,637,394.

Why It Matters

IRADIMED's strong revenue and net income growth demonstrate solid operational execution in the competitive medical device market, particularly for MRI-compatible products. This performance signals to investors that the company is effectively expanding its market reach and product adoption, potentially increasing shareholder value. For employees, continued growth could mean job security and opportunities for advancement. Customers benefit from the availability of specialized MRI-compatible medical devices, which are critical for patient safety and diagnostic accuracy. The company's reliance on FDA clearances and sole-sourced components, however, introduces supply chain and regulatory risks that could impact its competitive standing and market stability if not managed effectively.

Risk Assessment

Risk Level: medium — The risk level is medium due to IRADIMED's primary reliance on a limited number of products and the necessity of 510(k) clearance from the FDA and international regulatory bodies for its medical devices. Furthermore, the company's dependence on sole-sourced key components for its products presents a significant supply chain risk, as any disruption could have a 'materially adverse impact on our business, results of operations and financial condition.'

Analyst Insight

Investors should consider IRADIMED's consistent growth in revenue and net income as a positive indicator, but also monitor regulatory developments and supply chain stability closely. Diversification efforts in product offerings or component sourcing would de-risk the investment. Consider adding IRMD to a watchlist for further evaluation of its risk mitigation strategies.

Financial Highlights

debt To Equity
0.17
revenue
$61,122,101
operating Margin
31.2%
total Assets
$114,721,779
total Debt
$16,369,808
net Income
$16,038,042
eps
$0.43
gross Margin
77.4%
cash Position
$56,526,151
revenue Growth
+13.5%

Key Numbers

Key Players & Entities

FAQ

What were IRADIMED's revenues for the nine months ended September 30, 2025?

IRADIMED CORPORATION reported revenues of $61,122,101 for the nine months ended September 30, 2025, an increase from $53,852,954 in the same period of 2024.

How did IRADIMED's net income change in the third quarter of 2025?

For the three months ended September 30, 2025, IRADIMED's net income was $5,576,652, up from $5,049,491 in the third quarter of 2024.

What is IRADIMED's cash position as of September 30, 2025?

As of September 30, 2025, IRADIMED CORPORATION had cash and cash equivalents totaling $56,526,151, an increase from $52,233,907 at December 31, 2024.

What are the primary risks for IRADIMED's business operations?

Key risks for IRADIMED include the ability to receive and maintain 510(k) clearance from the FDA and other regulatory bodies for its medical devices, and the primary reliance on a limited number of products and sole-sourced key components, which could disrupt the supply chain.

How much did IRADIMED spend on property and equipment in the first nine months of 2025?

IRADIMED spent $7,470,826 on purchases of property and equipment during the nine months ended September 30, 2025, compared to $5,214,859 in the same period of 2024.

What was IRADIMED's gross profit for the nine months ended September 30, 2025?

IRADIMED CORPORATION achieved a gross profit of $47,292,106 for the nine months ended September 30, 2025, an increase from $41,589,022 in the prior year period.

How many shares of common stock did IRADIMED have outstanding as of October 31, 2025?

As of October 31, 2025, IRADIMED CORPORATION had 12,721,156 shares of common stock, par value $0.0001 per share, outstanding.

What is the significance of FDA clearance for IRADIMED's products?

FDA clearance is critical for IRADIMED's products as its medical devices require such clearance, along with international regulatory approvals, prior to commercialized sales. Failure to obtain or maintain these clearances could have a materially adverse impact on the business.

Did IRADIMED pay dividends in the nine months ended September 30, 2025?

Yes, IRADIMED paid dividends totaling $6,485,741 during the nine months ended September 30, 2025, which is lower than the $11,776,128 paid in the same period of 2024.

What is IRADIMED's business segment?

IRADIMED operates in one reportable segment, which focuses on developing, manufacturing, marketing, selling, and distributing Magnetic Resonance Imaging (MRI) compatible medical devices and products, along with related accessories, disposables, and services, primarily for hospitals and acute care facilities.

Risk Factors

Industry Context

Iradimed operates in the medical device industry, specifically focusing on non-invasive monitoring technologies. This sector is characterized by stringent regulatory oversight, particularly from the FDA, and a constant need for innovation to meet evolving healthcare demands. Competition can be intense, with established players and emerging companies vying for market share. The industry also faces supply chain complexities and the need for robust distribution networks.

Regulatory Implications

The company's reliance on FDA and international regulatory clearances is a significant factor. Any delays or adverse decisions in the approval process for new devices or modifications can directly impede market entry and revenue generation. Maintaining compliance with evolving global medical device regulations is critical for sustained operations and market access.

What Investors Should Do

  1. Monitor capital expenditure trajectory
  2. Analyze gross margin sustainability
  3. Evaluate operating cash flow trends

Glossary

Property and equipment, net
The value of a company's tangible assets used in operations, such as buildings, machinery, and vehicles, minus accumulated depreciation. (A significant increase from $16.8M to $23.8M indicates substantial capital investment in operational capacity or expansion.)
Retained earnings
The cumulative amount of net income that a company has kept over time, rather than distributing to shareholders as dividends. (An increase from $56.8M to $66.3M shows the company is generating profits and reinvesting them back into the business.)
Deferred revenue
Revenue that has been received by a company for goods or services that have not yet been delivered or rendered. (An increase in both current ($3.2M to $2.3M) and non-current ($3.6M to $3.0M) deferred revenue suggests strong future revenue streams from existing contracts.)
Net cash provided by operating activities
The total cash generated from a company's normal business operations over a period. (A slight decrease from $19.6M to $19.0M for the nine-month period, while still robust, warrants monitoring in conjunction with increased investing activities.)
Net cash used in investing activities
The total cash spent on investments, such as purchasing property, plant, and equipment, or acquiring other businesses. (An increase from $5.8M to $8.0M reflects the company's strategic investment in property and equipment.)

Year-Over-Year Comparison

For the nine months ended September 30, 2025, Iradimed Corp. demonstrated robust growth, with revenue increasing by 13.5% to $61.1M and net income rising by 13.8% to $16.0M, compared to the same period in 2024. The company significantly increased its investment in property and equipment, leading to a higher net cash used in investing activities. While operating cash flow saw a minor decrease, liquidity remains strong with an increase in cash and cash equivalents. No new material risks were explicitly highlighted in the provided text compared to the previous period's known risks.

Filing Stats: 4,170 words · 17 min read · ~14 pages · Grade level 20 · Accepted 2025-11-03 16:06:08

Key Financial Figures

Filing Documents

Financial Statements

Financial Statements 6 (a) Condensed Balance Sheets as of September 30, 2025 (Unaudited) and December 31, 2024 (Audited) 6 (b) Condensed Statements of Operations for the three and nine months ended September 30, 2025 and 2024 (Unaudited) 7 (c) Condensed Statements of Stockholders' Equity for the three and nine months ended September 30, 2025 and 2024 (Unaudited) 8 (d) Condensed Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 (Unaudited) 9 (e) Notes to Unaudited Condensed Financial Statements 10 Item 2

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 23 Item 4

Controls and Procedures

Controls and Procedures 24 Part II Other Information 25 Item 1

Legal Proceedings

Legal Proceedings 25 Item 1A

Risk Factors

Risk Factors 25 Item 2 Unregistered Sale of Equity Securities and Use of Proceeds 25 Item 3 Default Upon Senior Securities 25 Item 4 Mine Safety Disclosures 25 Item 5 Other Information 25 Item 6 Exhibits 26

Signatures

Signatures 27 2 Table of Contents CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING STATEMENTS Certain statements contained in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 (this "Quarterly Report") that are not historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. When used in this Quarterly Report the words "believe," "anticipate," "expect," "may," "will," "assume," "should," "predict," "could," "would," "intend," "targets," "estimates," "projects," "plans," and "potential," and other similar words and expressions of the future, are intended to identify such forward-looking statements, but other statements not based on historical information may also be considered forward-looking, including statements about the Company's future financial and operating results and the Company's plans, objectives, and intentions. All forward-looking statements are subject to risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to differ materially from any results, performance, or achievements expressed or implied by such forward-looking statements. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause the actual results to differ materially from the statements, including, but not limited to: our ability to receive 510(k) clearance for our products and product candidates, complete inspections conducted by the U.S. Food & Drug Administration (the "FDA") or other regulatory bodies resulting in favorable outcomes, additional actions by or requests from the FDA, including a request to cease domestic distribution

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Condensed Financial Statements

Item 1. Condensed Financial Statements IRADIMED CORPORATION CONDENSED BALANCE SHEETS September 30, December 31, 2025 2024 (unaudited) (audited) ASSETS Current assets: Cash and cash equivalents $ 56,526,151 $ 52,233,907 Accounts receivable, net of allowance for credit losses of $ 191,175 as of September 30, 2025, and $ 274,300 as of December 31, 2024 13,858,292 10,556,733 Inventory, net 11,734,822 10,401,889 Prepaid expenses and other current assets 1,097,330 1,513,680 Prepaid income taxes 1,702,410 536,010 Total current assets 84,919,005 75,242,219 Property and equipment, net 23,792,441 16,810,797 Intangible assets, net 3,373,478 3,098,691 Operating lease right-of-use asset — 154,688 Deferred tax asset, net 2,422,481 2,820,468 Other assets 214,374 198,912 Total assets $ 114,721,779 $ 98,325,775 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 2,333,474 $ 1,896,405 Accrued payroll and benefits 4,071,176 3,771,756 Other accrued taxes 296,207 162,998 Warranty reserve 137,025 118,269 Deferred revenue 3,158,065 2,259,616 Current portion of operating lease liabilities — 153,264 Other current liabilities — 150,000 Accrued income taxes 2,800,970 — Total current liabilities 12,796,917 8,512,308 Deferred revenue, non-current 3,572,891 2,993,287 Operating lease liabilities, non-current — 1,424 Total liabilities $ 16,369,808 $ 11,507,019 Stockholders' equity: Common stock; $ 0.0001 par value per share; 31,500,000 shares authorized; 12,721,156 shares issued and outstanding as of September 30, 2025, and 12,709,860 shares issued and outstanding as of December 31, 2024 $ 1,272 $ 1,271 Additional paid-in capital 32,007,647 30,026,734 Retained earnings 66,343,052 56,790,751 Total stockholders' equity 98,351,971 86,818,756 Total liabilities and stockholders' equity $ 114,721,779 $ 98,325,

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing